BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, January 10, 2025
See today's BioWorld Asia
Home
» Lee's sets sights on dry eye, gets fast track CFDA phase II approval
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Lee's sets sights on dry eye, gets fast track CFDA phase II approval
June 25, 2014
By
Shannon Ellis
No Comments
SHANGHAI – Another month, another announcement for Lee's Pharmaceuticals Ltd., of Hong Kong, as it has been slowly but surely building a successful biotech business and developing and commercializing products for the China market.
BioWorld Asia